$BARK
Bark, Inc.

2023 Q3 Form 10-Q Financial Statement

#000181957423000024 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $123.0M $120.6M $131.2M
YoY Change -14.45% -8.05% 11.52%
Cost Of Revenue $47.39M $47.56M $55.34M
YoY Change -25.33% -14.06% 15.73%
Gross Profit $75.64M $73.04M $75.81M
YoY Change -5.85% -3.66% 8.63%
Gross Profit Margin 61.48% 60.57% 57.81%
Selling, General & Admin $86.70M $87.04M $95.95M
YoY Change -3.11% -9.29% 10.74%
% of Gross Profit 114.62% 119.17% 126.56%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.070M $2.868M $3.262M
YoY Change 306.62% -12.08% 286.49%
% of Gross Profit 4.06% 3.93% 4.3%
Operating Expenses $86.74M $87.04M $95.95M
YoY Change -3.07% -9.29% 10.74%
Operating Profit -$11.10M -$14.00M -$20.14M
YoY Change 21.35% -30.46% 19.46%
Interest Expense $1.366M -$758.0K -$1.389M
YoY Change 1.94% -45.43% -188.98%
% of Operating Profit
Other Income/Expense, Net $132.0K $1.583M $6.119M
YoY Change -186.27% -74.13% -195.83%
Pretax Income -$10.34M -$11.66M -$15.41M
YoY Change -2.84% -24.31% -37.88%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.34M -$11.66M -$15.41M
YoY Change -2.84% -24.31% -37.88%
Net Earnings / Revenue -8.4% -9.67% -11.75%
Basic Earnings Per Share -$0.06 -$0.07 -$0.09
Diluted Earnings Per Share -$0.06 -$0.07 -$87.80K
COMMON SHARES
Basic Shares Outstanding 178.9M shares 178.3M shares 175.3M shares
Diluted Shares Outstanding 177.0M shares 177.7M shares 175.5M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $160.5M $163.9M $177.2M
YoY Change -3.49% -7.51% -44.78%
Cash & Equivalents $160.5M $163.9M $177.2M
Short-Term Investments
Other Short-Term Assets $4.300M $5.153M $13.53M
YoY Change -65.08% -61.91% 152.44%
Inventory $109.4M $112.5M $158.0M
Prepaid Expenses
Receivables $12.39M $5.128M $8.127M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $286.6M $286.7M $356.9M
YoY Change -19.63% -19.68% -18.29%
LONG-TERM ASSETS
Property, Plant & Equipment $28.72M $38.37M $74.57M
YoY Change -21.29% -48.55% 292.5%
Goodwill
YoY Change
Intangibles $11.61M $5.582M
YoY Change 232.65%
Long-Term Investments
YoY Change
Other Assets $7.271M $7.416M $4.414M
YoY Change 64.43% 68.01% -0.16%
Total Long-Term Assets $82.37M $87.18M $82.68M
YoY Change -6.67% 5.44% 219.67%
TOTAL ASSETS
Total Short-Term Assets $286.6M $286.7M $356.9M
Total Long-Term Assets $82.37M $87.18M $82.68M
Total Assets $369.0M $373.9M $439.6M
YoY Change -17.05% -14.96% -4.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.09M $19.55M $34.33M
YoY Change -42.38% -43.06% 3.43%
Accrued Expenses $35.50M $34.70M $31.45M
YoY Change -4.49% 10.32% -59.45%
Deferred Revenue $24.30M $26.30M
YoY Change -15.92%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $85.96M $80.59M $100.3M
YoY Change -22.78% -19.62% -29.09%
LONG-TERM LIABILITIES
Long-Term Debt $81.59M $81.41M $76.35M
YoY Change 6.64% 6.63% 6.66%
Other Long-Term Liabilities $4.389M $3.244M $56.83M
YoY Change -15.29% -94.29% 626.87%
Total Long-Term Liabilities $85.98M $84.65M $133.2M
YoY Change 5.24% -36.44% 67.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $85.96M $80.59M $100.3M
Total Long-Term Liabilities $85.98M $84.65M $133.2M
Total Liabilities $218.0M $211.9M $233.4M
YoY Change -10.91% -9.22% 5.72%
SHAREHOLDERS EQUITY
Retained Earnings -$331.8M -$321.5M
YoY Change 20.96%
Common Stock $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $150.9M $161.9M $206.2M
YoY Change
Total Liabilities & Shareholders Equity $369.0M $373.9M $439.6M
YoY Change -17.05% -14.96% -4.98%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$10.34M -$11.66M -$15.41M
YoY Change -2.84% -24.31% -37.88%
Depreciation, Depletion And Amortization $3.070M $2.868M $3.262M
YoY Change 306.62% -12.08% 286.49%
Cash From Operating Activities $2.820M -$10.74M -$17.43M
YoY Change -231.9% -38.36% -71.84%
INVESTING ACTIVITIES
Capital Expenditures $1.960M $2.972M -$4.735M
YoY Change -120.91% -162.77% -42.99%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.960M -$2.972M -$4.735M
YoY Change -79.09% -37.23% -42.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.450M -$221.0K 1.000K
YoY Change -860.68% -22200.0% -100.0%
NET CHANGE
Cash From Operating Activities 2.820M -$10.74M -17.43M
Cash From Investing Activities -1.960M -$2.972M -4.735M
Cash From Financing Activities -4.450M -$221.0K 1.000K
Net Change In Cash -3.590M -$13.93M -22.16M
YoY Change -67.14% -37.13% -107.81%
FREE CASH FLOW
Cash From Operating Activities $2.820M -$10.74M -$17.43M
Capital Expenditures $1.960M $2.972M -$4.735M
Free Cash Flow $860.0K -$13.71M -$12.69M
YoY Change -88.11% 8.06% -76.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 bark Class Of Warrant Or Right Number Of Warrants Called By Each Warrant Or Right Percentage
ClassOfWarrantOrRightNumberOfWarrantsCalledByEachWarrantOrRightPercentage
0.3333 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
178760600 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
177647754 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
177647754 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
-758000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
1389000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1583000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6119000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11663000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15408000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11663000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11663000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15408000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15408000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177681579 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
177681579 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
170537000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11663000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
286000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
530000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3225000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
161938000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
217061000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15408000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
154000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4343000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
206155000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11663000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15408000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2868000 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1871000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1073000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1391000 usd
CY2023Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
185000 usd
CY2022Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
161000 usd
CY2023Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2022Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
242000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3225000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
4343000 usd
CY2023Q2 bark Increase Decrease In Inventory Reserves
IncreaseDecreaseInInventoryReserves
600000 usd
CY2022Q2 bark Increase Decrease In Inventory Reserves
IncreaseDecreaseInInventoryReserves
319000 usd
CY2023Q2 bark Fair Value Adjustment Of Warrants And Derivatives
FairValueAdjustmentOfWarrantsAndDerivatives
-1304000 usd
CY2022Q2 bark Fair Value Adjustment Of Warrants And Derivatives
FairValueAdjustmentOfWarrantsAndDerivatives
-5997000 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1427000 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1383000 usd
CY2023Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-11269000 usd
CY2022Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5220000 usd
CY2023Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1602000 usd
CY2022Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
69000 usd
CY2023Q2 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
125000 usd
CY2022Q2 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
11000 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-14824000 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2497000 usd
CY2023Q2 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1427000 usd
CY2022Q2 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2932000 usd
CY2023Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-917000 usd
CY2022Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-746000 usd
CY2023Q2 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
474000 usd
CY2022Q2 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-119000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10741000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17425000 usd
CY2023Q2 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2972000 usd
CY2022Q2 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
4735000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2972000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4735000 usd
CY2023Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
58000 usd
CY2022Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
153000 usd
CY2023Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
81000 usd
CY2022Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
154000 usd
CY2023Q2 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
286000 usd
CY2022Q2 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 usd
CY2023Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
530000 usd
CY2022Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-221000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000 usd
CY2023Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000 usd
CY2022Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13932000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22154000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183068000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201679000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
169136000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179525000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163923000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
177242000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5213000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2283000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
169136000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179525000 usd
CY2023Q2 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
97000 usd
CY2022Q2 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1717000 usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
45000 usd
CY2022Q2 us-gaap Interest Paid Net
InterestPaidNet
73000 usd
CY2023Q2 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 usd
CY2022Q2 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
24576000 usd
CY2023Q2 bark Number Of Product Lines
NumberOfProductLines
2 productline
CY2023Q2 us-gaap Use Of Estimates
UseOfEstimates
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes estimates and assumptions about future events that affect the amounts reported in its condensed consolidated financial statements and accompanying notes. Future events and their effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates, judgments and assumptions.</span>The Company bases its estimates on historical and anticipated results and trends and on various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates, and any such differences may be material to the Company’s condensed consolidated financial statements. The most significant estimates relate to determination of fair value of the Company’s allowance for uncollectible accounts receivable, excess and obsolete inventory reserve, stock-based compensation, stand-alone selling price of Direct to Consumer offerings and fair value of right-of-use assets. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and records adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from those estimates.
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2023Q2 bark Number Of Leases Secured By Letter Of Credit
NumberOfLeasesSecuredByLetterOfCredit
4 lease
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5200000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5200000 usd
CY2023Q2 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Major Customers and Suppliers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents with one domestic financial institution of high credit quality. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are derived from sales contracts with large retail customers. The Company maintains reserves for potential credit losses on customer accounts when deemed necessary.</span></div>
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5484000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120591000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
131150000 usd
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
26300000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
27800000 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
81406000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
81221000 usd
CY2021Q2 bark Share Based Compensation Arrangement By Share Based Payment Award Options Minimum Exercise Price Grant Date Fair Value Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMinimumExercisePriceGrantDateFairValuePercentage
1
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
25000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.08
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3225000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4343000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
35820000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36892000 usd
CY2023Q2 bark Lease Right Of Use Asset
LeaseRightOfUseAsset
35820000 usd
CY2023Q1 bark Lease Right Of Use Asset
LeaseRightOfUseAsset
36892000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5136000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46672000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47240000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
51808000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
52724000 usd
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17000000.0 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
2000000.0 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
2200000 usd
CY2023Q2 bark Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
900000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
279000 usd
CY2022Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
123000 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1304000 usd
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5996000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1583000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6119000 usd
CY2023Q2 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
1400000 usd
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11663000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11663000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15408000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15408000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
177681579 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
177681579 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
175491912 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
175491912 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2023Q2 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
47555000 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
55336000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
73036000 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
75814000 usd

Files In Submission

Name View Source Status
0001819574-23-000024-index-headers.html Edgar Link pending
0001819574-23-000024-index.html Edgar Link pending
0001819574-23-000024.txt Edgar Link pending
0001819574-23-000024-xbrl.zip Edgar Link pending
bark-20230630.htm Edgar Link pending
bark-20230630.xsd Edgar Link pending
exhibit311-section302certi.htm Edgar Link pending
exhibit312-section302certi.htm Edgar Link pending
exhibit313-section302certi.htm Edgar Link pending
exhibit321-section906certi.htm Edgar Link pending
exhibit322-section906certi.htm Edgar Link pending
exhibit323-section906certi.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
bark-20230630_def.xml Edgar Link unprocessable
bark-20230630_lab.xml Edgar Link unprocessable
bark-20230630_pre.xml Edgar Link unprocessable
bark-20230630_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bark-20230630_cal.xml Edgar Link unprocessable